Heart transplant is the gold standard option for heart failure (HF) patients when all other options fail, says a cardiologist and heart failure specialist at the recent APSC 2017 Congress, with excellent long-term outcomes.
Lower total cholesterol-to-high density lipoprotein cholesterol ratio (TC:HDL) and low-density lipoprotein (LDL) levels appear to be associated with elevated mortality rates in patients with acute coronary syndrome (ACS), according to a study presented at the 21st Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Nonvitamin K antagonist (non-VKA) oral anticoagulants (NOACs) offer better outcomes than VKAs in Asian patients for the prevention of atrial fibrillation (AF)-associated stroke, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC) 2017 held in Singapore.
Short-term use (<30 days) of the anticoagulant warfarin following bioprosthetic aortic valve replacement (AVR) reduced the incidence of major adverse cardiovascular events (MACE) but not the risk of bleeding and re-operation, while long-term warfarin use (31–90 days) resulted in a higher incidence of MACE and reoperation, according to data presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Reduction of resting heart rate (RHR) with the beta-blocker (β-blocker) bisoprolol was associated with a decreased incidence of composite cardiovascular (CV) events in Chinese patients with coronary artery disease (CAD) according to a study presented at the Asian Pacific Society of Cardiology Congress (APSC 2017) held in Singapore.
Remodeling of the left atrium continues into middle and old age as a form of haemodynamic compensation for alterations in the structure and function of the heart, according to a study presented at the recently concluded 21st Asian Pacific Society of Cardiology Congress (APSC 2017).
Podcast: Dr Sara Hurvitz highlights that
the addition of ribociclib to endocrine therapy improved overall survival in
premenopausal women with HR+, HER2- advanced breast cancer, according to the
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
Patients referred to home hospice care following non-cancer diagnoses had their preventative medications significantly reduced between admission and death, though this did not apply to patients with cancer referred to hospice care, a retrospective study from Singapore showed.